Overview and History | 株式会社東洋厚生製薬所

Company Overview

Bankers: Tana Shinkin Bank Hino Branch,
Mizuho Bank Hinoekimae Branch
Mitsubishi UFJ Bank Hinoshiyakusyo Branch
Hokkoku Bank Tokyo Branch

Job description: Manufacture and marketing of pharmaceutical products
Export and import and marketing of pharmaceutical products
Manufacture and marketing of Pyro ligneous acid
Manufacture and marketing of refreshing beverages
Manufacture and marketing of supplements
All the businesses related above

Patent

Patent Number: 3411195
Title of Invention: Reactive Oxygen remover

The treatment of the disease caused by reactive oxygen and a prevention or the raw materials

Patent Number: 1617910
Title of Invention: Method for producing platinum or the palladium colloid

The manufacturing method of platinum group colloid by scattering fine particles of platinum / palladium in a solution.

Affiliated organizations: Society of PAPLAL research Director
Society of vitiligo and leukoderma research Member
Antioxidant Unit Supporting Member

1915: Dr. Noguchi Hideyo who was a student of the Rockefeller Institute for Medical Research came back to Japan only once in his life and then, he entrusted his best friend Saburo Ishizuka (dentist) research and development of Platinum/Palladium colloid (PAPLAL).
Since then, Ishizuka had advanced it with the written instruction from Dr. Noguchi who was living in the United States.

1936: To reward Dr. Noguchi who passed way before it's completion, Ishizuka finally completed PAPLAL with a lot of try-and-error by himself.
It had been 21 years for this only Platinum/Palladium colloidal preparation in the world to be born since he made a promise with Dr. Noguchi.

1938: Toyokosei Seiyakusyo was founded in 1 Naito-cho Shinjuku-Ku, Tokyo to officially manufacture and market PAPLAL.

1940: The trade mark "PAPLAL" was registered.
License of manufacture and marketing of pharmaceutical products was applied to the metropolitan police department at that time and was authorized.

1941: When manufacture and marketing of products were to begin seriously, the pacific war broke out.
Platinum and Palladium that were main raw materials became wartime control products so that it became difficult to obtain them and there was no way but suspending the production with the deterioration of the war.

1948: Toyokosei Seiyakusyo Co., Ltd. was founded.
The first director Saburo Ishizuka took office as the representative director and resumed the production of PAPLAL.
In response to Dr. Noguchi's wish "Medicine for those who are really in need", showy advertisement was refrained and that policy has been continued up to now.

1954: In the Yomiuri Shimbun morning edition (November 28th), it was greatly reported that "PAPLAL originated by Dr. Hideyo Noguchi is a specific medicine for the treatment of patients addicted to Philopon".

1956: "Medicalpractice of the rheumatism-related disease" issued on March 15th, page89 chapter 5 evaluated that "PAPLAL-Platinum/Palladium colloid preparation has greater effect on rheumatic arthritis than the Gold treatment and there is no side effect".

1961: New Pharmaceutical Affairs Law went into effect.
PAPLAL was evaluated as a medicine effective on acute gastroenteritis and chronic gastrointestinal catarrh.

1993: The head office and manufacturing facility moved to Hino City, Tokyo.
The size of colloidal particle of PAPLAL was measured by Dowa Kogyo Co., Ltd.
It was resulted in ultrafine particle (1.5nm). The minuteness of the particle was reassured.

1995: At the department of Polymer Science and Engineering of the Kyoto Institute of Technology, free radical oxygen removal activity was examined with the guidance of Professor Keisuke Makino, Kyoto University.
It was proved to be as much as 100 times of Vitamin C and got attention given from both inside and outside of Japan.

2015: The repigmentation effect of vitiligo vulgaris which is an intractable disease caused by the Platinum・Palladium Nano- colloid is announced by Koichi Shibata of the medical corporation Shibata skin clinic (※). At the same time, Society of vitiligo research was founded. Toyokosei Seiyakusyo had a membership from the beginning and started supporting with the wide range of the study.
(※It appeared in Journal of Pigmentary Disorders 2015.2.5)

2015: Society of PAPLAL research was founded in association with Musashino Pharmaceutical Co., Ltd.

2016: Research of PAPLAL was started by the industry-academia-government collaboration with the help of Hino city and Tokai University Medical department.

2017: The removability of four kinds Reactive Oxygen by the world’s first Platinum・Palladium Nano colloid became clear.

2017: In October, Okinawa Office was set up in Toyogusuku city, Okinawa for the research of the pyroligneous acid from Okinawa and as a circulation base of PAPLAL.

PATIENCE

A writing gifted by Dr. Noguchi in 1915